Cargando…
Targeting Malignant Brain Tumors with Antibodies
Antibodies have been shown to be a potent therapeutic tool. However, their use for targeting brain diseases, including neurodegenerative diseases and brain cancers, has been limited, particularly because the blood–brain barrier (BBB) makes brain tissue hard to access by conventional antibody-targeti...
Autores principales: | Razpotnik, Rok, Novak, Neža, Čurin Šerbec, Vladka, Rajcevic, Uros |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5622144/ https://www.ncbi.nlm.nih.gov/pubmed/28993773 http://dx.doi.org/10.3389/fimmu.2017.01181 |
Ejemplares similares
-
Development and characterization of a novel mAb against bilitranslocase - a new biomarker of renal carcinoma
por: Montanic, Sendi, et al.
Publicado: (2013) -
Prion Proteins Without the Glycophosphatidylinositol Anchor: Potential Biomarkers in Neurodegenerative Diseases
por: Kovač, Valerija, et al.
Publicado: (2018) -
Prion Protein: The Molecule of Many Forms and Faces
por: Kovač, Valerija, et al.
Publicado: (2022) -
Flavonoid Interaction with a Chitinase from Grape Berry Skin: Protein Identification and Modulation of the Enzymatic Activity
por: Filippi, Antonio, et al.
Publicado: (2016) -
TSE Diagnostics: Recent Advances in Immunoassaying Prions
por: Lukan, Anja, et al.
Publicado: (2013)